Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $441.63M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 1.77M
Average 3.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +69.0% | +52.5% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +69.0% over three years. Forward estimates point to Revenue at +52.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -5.44% |
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | $1.64B | $16.08 | Not rated | -4.6 | -45.95% |
Taysha Gene Therapies, Inc. NASDAQ:TSHA | $1.33B | $4.10 | Not rated | -17.7 | -5.99% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +7.39% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -60.47% |
Neurogene Inc. NASDAQ:NGNE | $378.15M | $23.93 | Not rated | -7.1 | +9.24% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -26.74% |
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | $235.59M | $2.87 | Not rated | -4.6 | -67.55% |
Abeona Therapeutics Inc. NASDAQ:ABEO | $138.30M | $2.42 | Not rated | 4.9 | -41.67% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -61.30% |
Continue the stock analysis
Jump to another research area for this company.